SOP Guide for Pharma

BA-BE Studies: SOP for Handling Serious Adverse Events (SAEs) – V 2.0

BA-BE Studies: SOP for Handling Serious Adverse Events (SAEs) – V 2.0

Standard Operating Procedure for Handling Serious Adverse Events (SAEs) in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/068/2025
Supersedes SOP/BA-BE/068/2022
Page No. Page 1 of 11
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To provide a clear, standardized procedure for the identification, assessment, documentation, management, and reporting of Serious Adverse Events (SAEs) in Bioavailability/Bioequivalence (BA/BE) studies.

2. Scope

This SOP applies to all clinical personnel and investigators involved in the monitoring, documentation, and reporting of SAEs that occur during BA/BE studies conducted at the clinical research unit.

3. Responsibilities

4. Accountability

The Principal Investigator is accountable for ensuring that all SAEs are identified promptly, managed appropriately, and reported within prescribed regulatory timelines.

5. Procedure

5.1 Definition of SAE

  1. Any untoward medical occurrence that:
    • Results in death
    • Is life-threatening
    • Requires hospitalization or prolongation of hospitalization
    • Results in persistent or significant disability/incapacity
    • Is a congenital anomaly/birth defect

5.2 Identification and Initial Response

  1. Nursing staff shall notify the Investigator immediately upon observation or report of any SAE-like symptoms.
  2. Provide emergency medical care and stabilize the subject.
  3. Document time of event and action taken in Annexure-1: SAE Initial Management Log.

5.3 Medical Assessment

  1. The Investigator assesses:
    • Severity and seriousness
    • Causality (related/unrelated/possibly related)
    • Outcome and need for hospitalization
  2. Details entered into Annexure-2: SAE Reporting Form.

5.4 Regulatory Reporting

  1. Report to the Sponsor, Ethics Committee, and Regulatory Authority (e.g., CDSCO) within 24 hours of awareness.
  2. Follow up with a detailed SAE report within 7 calendar days.
  3. Maintain submission proof in Annexure-3: Regulatory Communication Log.

5.5 Follow-Up and Final Assessment

  1. Conduct follow-up until resolution or stabilization of SAE.
  2. Update the SAE form and CRF with final outcome and Investigator signature.
  3. Attach supporting documents (discharge summary, lab results, etc.).

5.6 Review and Archival

  1. All SAE forms and documentation are reviewed by QA for completeness.
  2. Archived in Trial Master File (TMF) under safety documentation.

6. Abbreviations

7. Documents

  1. SAE Initial Management Log – Annexure-1
  2. SAE Reporting Form – Annexure-2
  3. Regulatory Communication Log – Annexure-3

8. References

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: SAE Initial Management Log

Subject ID Date & Time Event Description Immediate Action Taken By Whom
VOL-068 17/04/2025, 09:05 Severe hypotension Oxygen and IV fluids Dr. Arvind Shah

Annexure-2: SAE Reporting Form

Subject ID Event Start Date Severity Causality Outcome
VOL-068 Syncope 17/04/2025 Severe Possibly Related Recovered

Annexure-3: Regulatory Communication Log

Report Type Sent To Date Sent By Whom Acknowledgment
Initial SAE Report CDSCO 17/04/2025 Nisha Verma Yes

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial release Study compliance QA Head
17/04/2025 2.0 Added regulatory log, annexure details Regulatory update QA Head
Exit mobile version